Delivery Order SPE2DB20D3103-SPE2DB25FP8N4
- Not listed
- The Defense Logistics Agency awarded a $3,082.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with a completion date of August 21, 2025. This non-competitive award was issued to the company's corporate office located in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency has awarded a delivery order valued at $12,330.68 to AmerisourceBergen Drug Corp for the supply of BENLYSTA 200 mg/mL auto-injectors. The contract, issued on August 12, 2025, carries a firm fixed price arrangement with an ultimate completion date of September 3, 2025. No set-aside designation was applied to this competitive award. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on July 21, 2025, with completion scheduled for August 11, 2025. This is a firm fixed price, non-set-aside contract utilizing competitively awarded pricing. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on July 22, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $49,323 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 15, 2025. The contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's established indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price contract represents a non-competitive delivery order under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 22, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed-price, non-set-aside contract performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8N4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector, with an ultimate completion date of September 3, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters operations as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. Benlysta, a specialty medication for autoimmune conditions, represents one of many therapeutic products the company delivers through this framework agreement to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 8/12/25 |